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Although the genetic basis of Tourette Syndrome (TS) remains unclear, several candidate
genes have been implicated. Using a set of 382 TS individuals of European ancestry we
investigated four candidate genes for TS (HDC, SLITRK1, BTBD9, and SLC6A4) in an
effort to identify possibly causal variants using a targeted re-sequencing approach by next
generation sequencing technology. Identification of possible disease causing variants
under different modes of inheritance was performed using the algorithms implemented
in VAAST. We prioritized variants using Variant ranker and validated five rare variants via
Sanger sequencing in HDC and SLITRK1, all of which are predicted to be deleterious.
Intriguingly, one of the identified variants is in linkage disequilibrium with a variant that
is included among the top hits of a genome-wide association study for response
to citalopram treatment, an antidepressant drug with off-label use also in obsessive
compulsive disorder. Our findings provide additional evidence for the implication of these
two genes in TS susceptibility and the possible role of these proteins in the pathobiology
of TS should be revisited.
Keywords: next generation sequencing, targeted re-sequencing, genetic susceptibility, rare variants, TS candidate
genes, HDC, SLITRK1
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INTRODUCTION
Tourette Syndrome (TS; OMIM #137580) is a complex
neurodevelopmental disorder of childhood onset, characterized
by motor and vocal tics. It often presents with co-morbidities
such as attention deficit hyperactivity disorder (ADHD) and/or
obsessive-compulsive disorder (OCD), as well as mood disorders,
anxiety and sleep disorders. Apart from various environmental
factors that contribute to TS complexity (Hoekstra et al., 2013;
Mathews et al., 2014), twin and family studies have long
established that TS bears a strong genetic component (Price
et al., 1985; Pauls et al., 1991, 2014). However, despite extensive
on-going genetic research, concrete evidence supporting specific
pathogenetic mechanisms is still largely lacking. Several genes
(such as SLITRK1, HDC, NLGN4, CNTNAP2, IMMP2L, SLC6A4
also known as SERT, and NTN4) and chromosomal loci have
been implicated to date although, associations between genetic
variation and TS are often limited to specific population-
based cohorts or may be restricted to extremely rare mutations
identified solely in unique multigenerational pedigrees.
A very promising candidate TS susceptibility region was
implicated for the first time in 2005 by Abelson et al. (Abelson
et al., 2005). The study reported a de novo inversion in a TS
patient, occurring in the vicinity of the Slit and Trk-like family
member 1 (SLITRK1) gene. The authors subsequently sequenced
SLITRK1 in 174 unrelated TS probands and identified rare
mutations. This spurred intense interest in TS genetics with
multiple studies reporting rather mixed results (Abelson et al.,
2005; Deng et al., 2006; Keen-Kim et al., 2006; Wendland et al.,
2006; Chou et al., 2007; Scharf et al., 2008; Zimprich et al.,
2008; O’Roak et al., 2010; Karagiannidis et al., 2012). Recently,
our group and others have provided evidence for association of
the disorder with common alleles and haplotypes being over-
transmitted in TS cases; these findings support the hypothesis
of the existence of an as of yet unidentified risk factor in
linkage disequilibrium (LD) with the associated markers and
possibly lying in gene regulatory regions (Miranda et al., 2009;
Karagiannidis et al., 2012).
Abnormalities of cortico-striatal-thalamic-cortical
pathways and dysfunction of both dopamine and serotonin
neurotransmitter systems have long been considered in
association to TS (Peterson et al., 2003; Kalanithi et al., 2005;
Muller-Vahl et al., 2005). The recent implication of the L-histidine
decarboxylase (HDC) gene in TS etiology has also raised the
intriguing hypothesis of the involvement of histaminergic neural
pathways in the onset of the disorder (Ercan-Sencicek et al.,
2010; Lei et al., 2012). Moreover, a genome-wide scan for de
novo or transmitted rare copy number variants in TS had found
enrichment of genes within the histamine signaling pathways
(Fernandez et al., 2012). Subsequently, our group found evidence
for over-transmission of HDC alleles and significantly associated
haplotypes in trios of European origin (Karagiannidis et al.,
2013).
The serotonin transporter gene (SERT, 5-HTT), coding for a
solute carrier family 6 member 4 protein (SLC6A4) was reported
to carry both common and rare variants as well as a high-
expressing haplotype associated with increased gene expression
(5-HTTLPR/rs25531/rs25532) and protein activity (p.I425V),
thus potentially contributing to serotonergic abnormalities in TS
with or even more so, without OCD (Kilic et al., 2003; Moya
et al., 2013). These high-expressing alleles have been previously
significantly associated with OCD (Hu et al., 2006; Wendland
et al., 2008), which is believed to share a degree of common
genetic background with TS (Mathews and Grados, 2011; Yu
et al., 2015).
Variants in the BTB/POZ domain-containing protein 9 gene
(BTBD9) have been previously associated with restless legs
syndrome (RLS) (Allen et al., 2005; Winkelmann et al., 2007).
High RLS prevalence has also been reported in TS and, similar
to TS, it has been linked to frontostriatal circuits dysfunction
and is responsive to dopamine neurotransmission modification
(Turjanski et al., 1999). BTBD9 variants were found to be
associated with TS in French Canadian and Chinese patient
cohorts (Riviere et al., 2009; Guo et al., 2012). Yet, all analysed
variants were intronic and thus do not provide direct functional
relevance; however, they could be in LD with potentially
functional yet unknown variants, such as variants in gene
regulatory regions or, tissue and neuroanatomical region-specific,
naturally-occurring somatic mutations (Lodato et al., 2015).
The abovementioned TS susceptibility genes have emerged
from candidate gene association studies (SLC6A4, BTBD9),
chromosomal aberration studies (SLITRK1), and linkage analysis
studies (HDC). Despite decades of efforts in the field of
TS genetics, the overall number of identified variants likely
predisposing to TS remains extremely small. With the advent
of next-generation sequencing technology, there is a resurging
interest toward the identification of rare variants of potentially
intermediate-to-high penetrance effects that might aid in
explaining part of the missing heritability of the TS phenotype.
In the present study we report results on a targeted re-
sequencing approach in a cohort of 382 TS cases of European and
Canadian origin, aiming to explore the existence of rare genetic
variation across four genes that have attracted considerable
interest in the past years, namely SLITRK1, HDC, BTBD9,
and SLC6A4. Moreover, given the findings from our previous
studies on association of SLITRK1 and HDC haplotypes with TS
(Karagiannidis et al., 2012, 2013), we wanted to explore whether
previously associated risk haplotypes are in linkage with rare
coding, and thus directly functional variants in these two genes.
MATERIALS AND METHODS
Study Subjects
A total of 382 individuals with TS were included in the study.
The subjects represent affected cases from family trios who
had been previously recruited within The Tourette Syndrome
Genetics—Southern and Eastern Europe Initiative (TSGeneSEE)
and originated from Hungary (n = 117), Italy (n = 95), Poland
(n = 68), Greece (n = 17), and Albania (n = 8). In addition,
77 TS cases originating from Canada were also available. The
majority of these individuals have been described previously
(Karagiannidis et al., 2013). Assessment was performed by
on-site clinicians using the tools provided by the TS Association
International Consortium for Genetics (TSAICG, 2007). TS
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was ascertained according to DSM-IV-TR criteria for Italy,
Hungary, Albania, and Greece, and DSM-IV for Poland. For
Canadian samples, TS was ascertained using DSM-III-R criteria.
Differences between DSM-III-R, DSM-IV, and DSM-IV-TR are
minimal; the upper age limit of onset is 18 in DSM-IV (and
DSM-IV-TR) and 21 in DSM-III-R, and the “marked distress”
criterion, possibly pointing to more severe cases, only appears
in DSM-IV (applied only to the Polish cases; Cath et al., 2011).
For all samples, collection was approved by local Ethics Boards
and written informed consent was taken from all participating
individuals or their parents.
Genomic DNA Extraction
Peripheral blood samples were collected in EDTA-containing
tubes and genomic DNA was purified using the Qiagen Gentra
Puregene kit with minor protocol modifications (Qiagen GmbH,
Hilden, Germany).
Exome Capture and Targeted
Re-Sequencing
Using the Fluidigm custom panel design pipeline, the four
candidate genes (HDC, SLITRK1, SLC6A4, BTBD9) were targeted
for sequencing and custom primers were designed. For HDC
and SLITRK1, the whole locus including 1 kb upstream and
downstream were targeted. For SLC6A4 and BTBD9, exonic
regions of the genes were targeted (Table S1).
DNA samples were tagged and amplified using Fluidigm
Access Array System (Fluidigm Corporation, South San
Francisco, USA). The 48.48 Access Array integrated fluidics
circuit (IFC) protocol was followed. The sample mix solution
was prepared using 50 ng/uL of genomic DNA. The gDNA
was then combined with sample pre-mix and loaded into the
48.48 Access Array IFC. Upon amplification completion, the
IFC was placed on the Post-PCR IFC Controller AX and the
Harvest (151x) Script was run. After the completion of the
script 10 uL of the product was removed and placed into a
96-well PCR plate. Barcoding PCR was then set up using the
manufacturer’s instructions on a conventional PCR thermal
cycler. With the incorporation of a unique identifier or barcode
for each sample and the necessary sequencing adaptors,
it is possible to process all samples simultaneously on the
sequencing platform.
Quality and quantity of the library were evaluated on the
Agilent BioAnalyzer (Agilent Technologies, Santa Clara, CA, US)
and quantified using KAPA quantification. The sequencing was
then completed following the protocol for the Illumina (Illumina,
San Diego, CA) MiSeq V3 chemistry 2 × 100-bp paired-end
reads. Once the sequencing was completed, de-multiplexing was
performed using Illumina’s bcl2fastq2 v2.15 to generate sample
specific fastq files.
Sequence Alignment and Genotype Calling
Sequence alignment was performed using Burroughs Wheeler
alignment (BWA; Li and Durbin, 2009) using the reference
human genome build hg19 from UCSC. Samtools (Li et al., 2009)
was used to convert BAM alignment files to SAM format and
then sort and index them. INDEL realignment was performed
using IndelRealigner and base quality score recalibration was
performed using BaseRecalibrator from GATK (McKenna et al.,
2010). PCR and optical duplicates were removed from samples
using Picard (http://picard.sourceforge.net). Variant calling was
done on the targeted regions (Table S1) by combining all the
samples using the GATK pipeline and following their best
practices protocol. Further filtering was applied to keep only the
variants that passed the quality control filters and 95% genotype
call rate. Sequencing data (BAM files) can be accessed via http://
paschou-lab.mbg.duth.gr/share_data.html.
Variant Ranker Analysis
Variants were then annotated using ANNOVAR (Wang
et al., 2010) and ranked using Variant Ranker tool (http://
paschou-lab.mbg.duth.gr/Software.html). Variant ranker
aggregates annotation information based on allelic frequency
scores, conservation scores, prediction algorithm scores, and
clinical information. Using Variant Ranker, the variants are
prioritized on the basis of their effect, novelty, and annotation
information. A variant was designated as novel if not present
in database of human variation dbSNP build 138 and had a
minor allele frequency (MAF) ≤0.01 in 1000 Genomes, Exome
Aggregation Consortium (ExAC) and National Heart, Lung, and
Blood Institute Exome Sequencing Project (NHLBI ESP6500)
database.
VAAST Analysis
Scoring and prioritization analysis of deleterious alleles was
performed using VAAST 2.0 (Hu et al., 2013). We applied the
likelihood ratio test in VAAST using both dominant and recessive
disease models of inheritance, with the help of a background
file comprising of 189 genomes from 1000 Genomes project
(Abecasis et al., 2012), 184 Danish exomes (Li et al., 2010), 10Gen
genome dataset (Reese et al., 2010), and 40 whole genomes from
the Complete Genomics Diversity Panel.
Identification of Linkage Disequilibrium
(LD) SNPs
We used the web-based application LDproxy (Machiela and
Chanock, 2015) to identify proxy LD SNPs and LdOOKUP
(http://purces04.u.hpc.mssm.edu/ldookup/ldookup.cgi) to
browse for variants in LD with other GWAS studies from the
Psychiatric Genomics Consortium, brain eQTL data and the
NHGRI GWAS catalog (Welter et al., 2014).
Sanger Sequencing
PCR primers were designed using PRIMER3 (http://primer3plus.
com) and confirmed to have unique genomic product by UCSC
in-silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr), targeting
amplicons of sizes between 300 and 400 bp. PCR products
were purified using QIAquick PCR purification kit from Qiagen
(QIAGEN, CA), followed by Sanger sequencing on an ABI 3730xl
sequencer in Genscript (NJ, USA), using the BigDye Terminator
v.3.1 chemistry.
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RESULTS
Identification of Variants
We explored whether coding variations in four genes,
namely, HDC, SLITRK1, BTBD9 and SLC6A4 play a role in
TS susceptibility. We utilized next-generation sequencing
technology to perform targeted sequencing on a total of 60
kilobases, including the entire HDC and SLITRK1 genes, and
spanning 15 exons of SLC6A4 and 11 exons of BTBD9 genes,
across 382 TS cases of Caucasian origin (Table S1). Regarding
data quality, more than 95% of bases were sequenced with
>99.9% accuracy, covering most amplicons at >100X.
We obtained 336 single nucleotide polymorphisms (SNPs)
with 31 exonic SNPs (see summary statistics on Table 1). We
focused only on functionally important non-synonymous exonic
variants and pursued validation via Sanger sequencing. We
found a novel rare (MAF = 0.13%) variant in HDC residing
in exon 12 (HDC:NM_002112:exon12:c.A1564C:p.I522L),
two rare (MAF = 0.13%) novel SLITRK1 variants, at
positions chr13:g.84454582 (SLITRK1:NM_052910:exon1:
c.G1061C:p.G354A). and chr13:g.84454485 (SLITRK1:NM
_052910:exon1:c.G1158T:p.K386N), residing in exon 1 of the
gene, and two known rare variants, rs146746846 (MAF =
0.13%) (SLITRK1:NM_052910:exon1:c.C892T:p.H298Y) and
rs150504822 (MAF = 0.26%; SLITRK1:NM_052910:exon1:
c.A1252T:p.T418S), also in exon 1 (Table 2). The five confirmed
variants were ranked within the top six potentially etiologically
relevant variants by our Variant Ranker algorithm and were
all predicted to be deleterious by MutationTaster functional
prediction algorithm (Schwarz et al., 2010; Table S2). One
confirmed SLITRK1 variant (rs146746846) was also identified by
VAAST under a recessive model of inheritance (Table S3). Proxy
LD SNPs available for rs150504822 on SLITRK1 were input
into LdOOKUP to identify significant variants in other GWAS
studies. A variant in LD with rs150504822, namely rs6563353,
was identified (Tables S4, S5); rs6563353 has been positively
associated (p = 2.06e-6) with increased citalopram-induced
general side effect burden, in patients with depression (Adkins
et al., 2012). Citalopram is an antidepressant drug of the selective
serotonin reuptake inhibitor class, with an off-label use for OCD
treatment.
DISCUSSION
To our knowledge, this is the first study applying next generation
sequencing technology in quest for genetic susceptibility variants
shaping the genomic landscape of TS. It is expected that at
least part of the missing heritability of complex disorders,
such as TS, will be attributable to low-frequency variants with
intermediate penetrance effects (Manolio et al., 2009) and, if
truly causative, they could account for a small proportion of TS
cases.
In the present study, we identified and confirmed a rare novel
HDC coding variant as well as two rare novel and two rare known
SLITRK1 coding variants, all confirmed by Sanger sequencing
(Table 2). We did not extensively cover the regulatory regions
of the genes; thus, regulatory variants may have been missed
TABLE 1 | Summary of functional annotation of identified variants.
Variant category Number of variants
Upstream 23
5′UTR 9
Coding (Exonic) 31
Intronic 205
3′UTR 40
Downstream 17
Intergenic 11
Total 336
Nonsynonymous 17
Synonymous 14
Total Coding 31
UTR, Untranslated region.
resulting in under-estimation of the contribution of these genes
to TS risk.
The recent implication of the L-histidine decarboxylase
(HDC) gene in TS etiology has raised the intriguing hypothesis
of the involvement of histaminergic neural pathways in the
onset of the disorder. Ercan-Sencicek et al. studied a family
with a father and all eight of his children affected with TS,
and found a rare premature termination codon mutation
(p.W317X) in HDC, also absent in 3,000 control individuals.
Due to the demonstrated dominant-negative mode of function
of the mutant HDC enzyme, the authors concluded that
histaminergic neurotransmission is most likely diminished in
their patients (Ercan-Sencicek et al., 2010). However, HDC
coding variants seem to be extremely rare since apart from
the mutation identified in the original pedigree, HDC has
not been found altered in other TS cases of Caucasian or
Asian origin (Ercan-Sencicek et al., 2010; Lei et al., 2012).
Interestingly, a preceding genome-wide study of 95 French
Canadian trios with familial history of TS (Riviere et al., 2010)
had also shown association to a microsatellite marker on
chromosome 15 (D15S1016), lying within the same interval
found to be linked with TS in the original study that implicated
HDC in TS etiology. Finally, a recent genome-wide scan for
de novo or transmitted rare copy number variants in TS found
enrichment of genes within the histamine receptor signaling
pathways (Fernandez et al., 2012). Even though in the present
study we did not detect the rare variants previously reported in
the literature, we did find a novel exonic nonsynonymous
variant, chr15:g.50534882 (c.A1564C:p.I522L), in one
TS case.
Histamine plays a central role in gastric acid secretion,
innate, and acquired immunity and immunomodulation,
bronchoconstriction, vasodilation and neurotransmission. The
neuronal histaminergic system is involved in a number of
basic physiological functions such as circadian rhythmicity,
energy metabolism, neuro-endocrine homeostasis, stress,
sensory, and motor functions, cognition, attention, learning,
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TABLE 2 | Nonsynonymous variants confirmed by Sanger sequencing.
Location Ref/Alt Het Gene RefGene variant annotation 1000G LRT MutationTaster
chr13:84454582 C/G 1 SLITRK1 SLITRK1:NM_052910:exon1:c.G1061C:p.G354A NA D D
chr13:84454485 C/A 1 SLITRK1 SLITRK1:NM_052910:exon1:c.G1158T:p.K386N NA D D
chr13:84454751(rs146746846) G/A 1 SLITRK1 SLITRK1:NM_052910:exon1:c.C892T:p.H298Y NA D D
chr13:84454391(rs150504822) T/A 2 SLITRK1 SLITRK1:NM_052910:exon1:c.A1252T:p.T418S 0.00019 D D
chr15:50534882 T/G 1 HDC HDC:NM_002112:exon12: c.A1564C:p.I522L NA N D
Chr, chromosomal location; Ref, Reference allele; Alt, Alternative (rare) allele; Het, Number of heterozygous cases with the variant; 1000G, 1000 Genomes Project variant frequency (if
available); LRT, Likelihood Ratio Test; LRT D, Deleterious; N, Neutral; MutationTaster D, Disease-causing; NA, Not available.
and memory. Histidine decarboxylase (HDC) is the key enzyme
for histamine production from histidine and in the brain its
mRNA is expressed exclusively in the posterior hypothalamus
(Haas et al., 2008). So far, the histaminergic system has not
received as much attention as other monoaminergic systems of
the brain. Classically established as a “peripherally” important
mediator of inflammation, the importance of histamine in
neurotransmission, and its role in neuropsychiatric disorders
is only recently starting to become appreciated (Tiligada et al.,
2011) and deserves further investigation also in the context
of TS. Interestingly, Hdc−/− deficient mice have several traits
relevant to features of TS and have shown decreased brain
histamine and increased sensitivity to stereotypic behaviors (i.e.,
hyperlocomotion) upon administration of dopamine agonists
(Kubota et al., 2002) and repetitive grooming after induced fear
(Xu et al., 2015). Such stimulant-induced movements, including
rearing, sniffing, and biting have previously been proposed as a
model of human tics (Saka and Graybiel, 2003; Castellan Baldan
et al., 2014).
SLITRK1 has been extensively studied since its identification
as a much promising TS candidate gene. However, with the
exception of the variants reported by Abelson et al. (2005),
additional novel non-synonymous mutations have not been
identified in a large number of subsequent studies interrogating
patient cohorts (Deng et al., 2006; Chou et al., 2007; Scharf et al.,
2008; Zimprich et al., 2008) or single families (Robertson and
Orth, 2006; Verkerk et al., 2006; Fabbrini et al., 2007; Pasquini
et al., 2008). On the other hand, genetic association studies and
haplotype analyses could not rule out the implication of SLITRK1
in TS etiology either via the existence of risk factors in LD with
SLITRK1 (Miranda et al., 2009) or as of yet unidentified SLITRK1
regulatory variants (Karagiannidis et al., 2012). In our study, we
did not detect the SLITRK1 variants that had been previously
reported in association to TS but we report on the identification
of two novel variants, chr13:g.84454582 and chr13:g.84454485,
each found in one TS patient. We also identified two rare non-
synonymous SLITRK1 variants (rs150504822 and rs146746846,
identified in two TS cases and one TS case, respectively).
Interestingly, rs150504822 was found in LD with rs6563353,
a variant that has been previously associated with citalopram-
induced general side-effect burden in patients with depression
(Adkins et al., 2012). Citalopram, is a well-tolerated acute
treatment drug conferring positive response in children and
adolescents with OCD (Thomsen et al., 2001; Mukaddes et al.,
2003).
Interestingly, SLITRK1 encodes a transmembrane protein
necessary for dendritic growth, axon guidance and branching
of neuronal cells. It is expressed in both the embryonic
and postnatal brain (cortex, thalamus, and basal ganglia),
reflecting neuroanatomical regions most commonly affected in
TS (Proenca et al., 2011), as well as in mature neurons with large
axons (Aruga and Mikoshiba, 2003). Slitrk1−/− mice exhibited
elevated anxiety and depression-like behaviour, consistent with
TS symptoms, in which the anxiety-like behaviour was attenuated
upon clonidine administration, a drug often used in TS treatment
(Katayama et al., 2010).
Our previous and present studies suggest that SLITRK1 and
HDC may have an under-appreciated role in TS aetiology.
Unarguably, the functional role of the identified variants warrants
further investigation by a wide array of experiments. Next-
generation sequencing technology is rapidly becoming a routine,
albeit still costly approach to target patient genomes that is
expected to significantly expedite the quest for rare variants with
reduced penetrance, not only in TS susceptibility but also other
complex neurodevelopmental and neuropsychiatric disorders.
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